Phase II Study of Chemoradiation for Early Stage Vulvar Cancer with Sentinel Node Metastasis Larger Than 2mm
Led by University Medical Center Groningen · Updated on 2023-08-01
157
Participants Needed
27
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate a new treatment approach for early-stage vulvar cancer patients who have sentinel lymph node SN metastases larger than 2mm. Traditionally, these patients undergo an inguinofemoral lymphadenectomy IFL, a surgery linked to significant side effects like wound problems and leg swelling. Previous studies showed that radiotherapy alone was not enough for larger metastases, so this trial tests adding chemotherapy to improve treatment.
Participants receive chemoradiation, which includes inguinofemoral radiotherapy totaling 56 Gy over 5 to 6 weeks, combined with weekly intravenous cisplatin chemotherapy. The radiotherapy is delivered in daily doses with a focused boost to affected lymph nodes. This study is a phase II trial designed to monitor safety and effectiveness, with rules to stop if groin recurrences become too frequent.
During the study, participants will be closely monitored for groin recurrences within the first two years after treatment. Assessments include checking for treatment-related side effects, quality of life surveys specific to vulvar cancer, and regular follow-up visits. Researchers aim to gather detailed information about the safety of replacing surgery with chemoradiation and the impact on patients well-being over time.
CONDITIONS
Brief Title
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
Research Team
M
Maaike H Oonk, MD PhD
L
Liza Lahaye
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
A study treatment that combines radiotherapy to the groin area with weekly cisplatin chemotherapy. This regimen is specifically offered to women with vulvar cancer who have sentinel lymph node metastases after biopsy.
Surgical removal of all groin lymph nodes, known as inguinofemoral lymphadenectomy, which is considered the standard care for patients with vulvar cancer and positive sentinel lymph nodes after biopsy.
Role in study/trial
The only active treatment given to all participants in the GROINSS-V III trial.
Not given within the trial but is the established treatment for similar patients outside the study.
Primary use
Aims to treat groin lymph node metastases after sentinel node-positive biopsy in women with vulvar cancer, potentially avoiding complete groin lymph node removal.
Definitively treats groin lymph node metastases by surgically removing affected nodes and reducing recurrence risk.
How it is given or performed
Patients receive radiotherapy targeted to the groin lymph nodes combined with intravenous cisplatin once a week during the treatment course.
A surgery performed under anesthesia, where all groin lymph nodes are removed through an inguinal and femoral incision.
Evidence status
Still under investigation; trial is ongoing and results for recurrence rates and safety are not yet established.
Supported by long-term clinical experience and highlighted in guidelines as the default approach with proven effectiveness for local control.
Important risks or side effects
Potential risks include acute effects from radiation (such as skin reaction or swelling), chemotherapy-related toxicity, and delayed wound healing. The risk profile is still being studied in this trial.
Common important risks are long-term lymphedema (swelling of the leg), wound breakdown, infection, and lymphocele (collection of lymph fluid), as described in published evidence and international guidelines.
Important limitations
Long-term effectiveness and comparative recurrence risk are not yet established. The regimen may carry risks of skin and soft tissue toxicity, and cumulative evidence for quality of life is still limited to ongoing study.
Known for significant risk of chronic lymphedema and surgical complications, which can impact quality of life even after successful cancer treatment.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
FEMALE
Eligibility Criteria
You may qualify if you...
Histologically confirmed primary squamous cell carcinoma of the vulva
T1 tumor not involving the urethra, vagina, or anus
Depth of tumor invasion greater than 1 mm
Tumor diameter less than 4 cm
Unifocal tumor
No enlarged or suspicious inguinofemoral lymph nodes on imaging
Ability to provide informed consent
Metastatic sentinel lymph node with metastasis larger than 2 mm and/or extracapsular extension, or more than one sentinel node with metastasis 2 mm or smaller
Ability to understand study requirements and comply with procedures
Adequate bone marrow, kidney, and liver function as defined by specific blood counts and chemistry
Performance status of 0, 1, or 2 on ECOG scale
Age 18 years or older
Life expectancy of at least 12 weeks
Written informed consent obtained
You will not qualify if you...
Inoperable tumors or tumors larger than 4 cm
Multifocal tumors
Tumors with pathology other than squamous cell carcinoma
Enlarged or suspicious lymph nodes confirmed metastatic by fine needle aspiration
Other carcinomas within the last 5 years except basal cell carcinoma
History of pelvic radiotherapy
Recent infection requiring hospitalization or antibiotics within 2 weeks before enrollment
Pregnant or nursing females
Desire to become pregnant
Known untreated or progressive brain or spinal cord metastases
Recent unstable heart conditions or severe congestive heart failure within 6 months prior to enrollment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 5 to 6 weeks
Participants receive chemoradiation consisting of inguinofemoral radiotherapy combined with weekly cisplatin for early stage vulvar cancer with sentinel node metastasis.
Weekly visits for chemoradiation over 5 to 6 weeks
Follow-up
Duration - Up to 2 years
Participants are monitored for groin recurrence and treatment-related morbidity, with assessments of quality of life over the first two years after treatment.
Regular follow-up visits during the first 2 years after treatment
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Comparing Axillary Radiotherapy and Lymph Node Dissection
in Breast Cancer Patients with Positive Sentinel Nodes After Neoadjuvant Therapy
Evaluating EndoScell Cellular Imaging Technology for Breast-Conserving Surgery and Sentinel Lymph Node Biopsy in Early Breast Cancer
Study of Atezolizumab and Tivozanib for Treatment of Advanced Immunologically Cold Cancers Including Prostate, Bile Duct, Breast, Neuroendocrine, Ovarian, Pancreatic, Sarcoma, and Vulvar Cancers
Study Comparing No Further Axillary Treatment Versus Standard Axillary Treatment in Early Breast Cancer Patients with Lymph Node Metastases After Chemotherapy
Phase II Study of Belzutifan for Recurrent or Persistent Clear Cell Carcinoma in Female Gynecologic Cancers
Near-Infrared Image-Guided Lung Lesion Removal and Targeted Lymph Node Mapping Using Indocyanine Green
Cancer Loyalty Card Study 2 Using Shopping Data to Detect Early Signs of Ten Cancer Types in Adults in the UK
Study Comparing Two-Point Versus Four-Point Methylene Blue Injection
for Sentinel Lymph Node Mapping in Early Stage Endometrial Cancer
Study on Using Patient-Reported Outcomes and Circulating Tumor-DNA to Detect Early Recurrence of Vulva Cancer in Women
Study of Delayed Sentinel Lymph Node Biopsy Using SPIO Nanoparticles in Women With Ductal Carcinoma In Situ or Suspicious Breast Lesions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Phase II activity trial of high-dose radiation and chemosensitization in patients with macrometastatic lymph node spread after sentinel node biopsy in vulvar cancer: GROningen INternational Study on Sentinel nodes in Vulvar cancer III (GROINSS-V III/NRG-GY024).
Lilian T Gien, Brian Slomovitz, Ate Van der Zee...